SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
August 24, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
August 08, 2016 09:05 ET
|
SCYNEXIS, Inc.
Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078 Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As...
SCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference
August 04, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference...
SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
August 01, 2016 08:00 ET
|
SCYNEXIS, Inc.
Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE...
SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
July 13, 2016 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based...
SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
July 06, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald’s 2nd Annual...
SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
June 21, 2016 09:15 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and...
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
June 20, 2016 16:02 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., June 20, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants...
SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections
June 20, 2016 08:00 ET
|
SCYNEXIS, Inc.
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humansFungicidal activity of SCY-078 demonstrated against multiple Candida species, including...
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
June 10, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the...